ArticleEJNMMI research2025
Single-center experience comparing glass and resin microspheres in lobar Y-90 SIRT for early- to intermediate-stage hepatocellular carcinoma.
Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSelective internal radiation therapy (SIRT) with yttrium-90 (Y-90) microspheres is an established locoregional treatment for early- to intermediate-stage hepatocellular carcinoma (HCC). While both resin and glass microspheres are widely used, their comparative effectiveness and safety in lobar infusion remain unclear. This study aimed to compare the effectiveness and safety of resin versus glass microspheres in patients with early- to intermediate-stage HCC undergoing lobar Y-90 SIRT.
resultsA retrospective single-center analysis was conducted on 37 consecutive patients with early- to intermediate-stage HCC who underwent lobar Y-90 SIRT (resin: n = 22; glass: n = 15). Baseline characteristics were comparable between the two groups, except for age (glass: 64 ± 6.9 years vs. resin: 69 ± 7.1 years; P = 0.036). Radiation doses to the tumour and non-tumoural liver were comparable between the resin and glass groups (all P > 0.05). Patients treated with resin microspheres showed significantly longer progression-free survival (PFS) (median 9.3 vs. 6.4 months; P = 0.043) and overall survival (OS) (median 16.4 vs. 12.0 months; P = 0.035), and also demonstrated higher overall response rates, compared with those treated with glass microspheres. Univariate Cox regression identified resin microsphere use as a significant predictor of improved PFS and OS, while higher Barcelona Clinic Liver Cancer (BCLC) stage, multifocal disease, and tumour burden ≥ 25% were associated with worse survival (all P < 0.05). Fine-Gray competing risk regression, accounting for post-SIRT treatments as competing events, further confirmed the OS benefit of resin microspheres compared with glass microspheres (subdistribution hazard ratio [SHR] = 0.35; P = 0.011). Subgroup analysis demonstrated that the survival advantage of resin microspheres was particularly evident in patients with a maximum tumour diameter ≥ 5 cm (PFS: hazard ratio [HR] = 0.258, 95% confidence interval [CI]: 0.073-0.914; OS: HR = 0.111, 95% CI: 0.013-0.962). Safety outcomes were comparable between the two groups, with no significant differences in short- to long-term adverse events graded according to the Common Terminology Criteria for Adverse Events version 5.0, or in laboratory changes at 4-month follow-up (all P > 0.05).
conclusionsIn lobar Y-90 SIRT for early-to intermediate-stage HCC, resin microspheres were associated with improved outcomes without increased toxicity compared to glass microspheres, particularly in patients with large tumours. These findings support a potential benefit of resin versus glass microspheres in lobar SIRT and warrant prospective validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.